Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV versus oral iron before pediatric spinal fusion
ACTRN12618000917235Phase 3Not yet recruiting
- Sponsor
- Dr Rebecca Munk
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose, ferrous sulfate and ferrous fumarate in iron deficiency anemia (IDA) and anaemia (2 arms), sponsored by Dr Rebecca Munk. Primary endpoint: Incidence of severe anaemia at discharge. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
ferric carboxymaltoseferrous sulfateferrous fumarate
03
Conditions
iron deficiency anemia (IDA)anaemia
Beyond the preview
Go deeper on ACTRN12618000917235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000917235.